Literature DB >> 12758158

Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1.

Alon Herschhorn1, Arie Admon, Amnon Hizi.   

Abstract

Inhibitory antibodies to the reverse transcriptase (RT) of human immunodeficiency virus type-1 (HIV-1) can be used to block the life cycle of the virus. We have isolated five different human single chain Fv (ScFv) antibodies specific for HIV-1 RT from an antibody phage display library. Three of these antibodies inhibited the RNA-dependent DNA polymerase (RDDP) activity of RT and one of the three (F-6) inhibited also its DNA-dependent DNA polymerase (DDDP) activity. Unexpectedly, F-6 binds to the carboxyl terminus of the large subunit of RT, which contains the ribonuclease H (RNase H) domain, and not the polymerase domain of the protein. Moreover, this binding did not inhibit the RNase H enzymatic activity. To further characterize F-6 antibody, two cyclic synthetic peptides based on the amino acids sequences of the CDR3 of F-6 were synthesized. Peptide F-6CDRH3, with the sequence of CDR3 of the heavy chain, inhibited the RDDP activity of RT while peptide F-6CDRL3, with the sequence of CDR3 of the light chain, had no effect on this activity of RT. These results indicate that some of the effects of F-6 are mediated by the CDR3 of the heavy chain. The antibodies identified here will be further tested as intrabodies for their capacity to protect human cells from HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12758158     DOI: 10.1016/s1570-9639(03)00118-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

Review 1.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

Review 2.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.